Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Ibrutinib & Rituximab is a new standard for WM Design trials that use the combination as a backbone at Annual Meeting 2018
Advertisement
Ibrutinib & Rituximab is a new standard for WM Design trials that use the combination as a backbone
By Editor